GRNAW.US Warrant Exchange Offer

GreenLight Biosciences Holdings, PBC has offered an “Exercise option” for GRNAW.US, The Exercise price was reduced to $0.2780 per Warrant (reduction in the exercise price for 30 days between July 20, 2023, and August 23, 2023).  MERGER CONSIDERATION: upon exercise warrant holders are entitled to a merger consideration of $0.30. as such, for exercises through August 23, 2023. ALL EXERCISES WILL RESULT IN THE NET PAYMENT OF CASH OF $0.0220 PER WARRANT EXERCISED. (WHICH WILL BE THE MERGER CONSIDERATION MINUS THE REDUCED EXERCISE PRICE). The exercise price will revert to $11.50 per share after August 23, 2023.

Please note: No shares of common stock will be issued. The exercise price will revert to $11.50 per share after August 23, 2023.

The terms of the offer are as follows:

Option (1) : Take no action [Default option]


The deadline to tender shares to the offer will be 16/08/2023@ 16:00 (HONG KONG TIME GMT+8).

Please fill in the following information and use the registered email address of Futu to send an email to cs@futuhk.com.

1. Account Number –
2. Name - (In Chinese or English)
3. Stock code – GRNAW.US
4. Options - (1) or (2)
5. Number of shares participating in corporate actions -

Note to applicants:
1. If shareholders holding 1 stock warrants less of GRNAW.US, they cannot participate in related corporate actions.
2. Option 1 is the default option. We will help clients to choose option 1 if have not received clients’ emails.
3. Once the relevant application is submitted, the stocks participating in the company's actions cannot be traded and the application cannot be withdrawn.
4. This corporate action does not accept additional applications, the maximum number of applications that a client can apply for does not exceed the number of eligible shares it holds.
5. The pending orders and unsettled shares will not be accepted for the time being.
6. Please confirm that the account funds are sufficient to pay the relevant fees of this corporate action. Otherwise, we will not bear any responsibility for the failure of your application.
7. If there is any update, all the information released by the listed company shall prevail.